Costs and resource use

Economic evidence

No published economic evidence was found.

The developer provided a budget impact model that evaluates the cost-saving potential for a single NHS clinical commissioning group if Sleepio were introduced in 50% of eligible patients (defined as people with insomnia having cognitive behavioural therapy [CBT‑I]). The model used recovery rates from Luik et al. (2017). The analysis does not satisfy the requirements of a model-based economic evaluation but suggests that Sleepio has cost-saving potential. Cost savings would most likely result from a reduction in direct treatment costs compared with face-to-face CBT‑I, but only if Sleepio were used instead of CBT‑I. Cost savings in terms of reduced hypnotic drug prescribing and further primary and secondary care contact depend on the longer-term relative effectiveness of Sleepio. There is no published evidence directly comparing Sleepio with face-to-face therapy, or that provides long-term outcomes on which to judge the likelihood of savings.

Technology costs

Sleepio costs £200 per year, or £3.85 per week. After the first year, users may renew as 'graduate' users at a reduced price of £5.99 per month. Pricing models for the NHS may vary depending on the number of users, so discounts may be available.

Comparator costs

Hypnotic drugs include short-acting benzodiazepines and non-benzodiazepines. These should not be taken for more than 3 weeks and preferably for only a week. Assuming that the maximum adult dose is taken each day, it costs around £1.50 to £9.00 for a week's course and £4.50 to £27.00 for a 3‑week course (British National Formulary 2016). A conventional CBT‑I session lasts around 55 minutes and costs £97 (Personal Social Services Research Unit 2016), which amounts to £582 for 6 sessions.

Potential resource impact

Sleepio could be cost saving if it were shown to be as effective as face-to-face CBT‑I (£200 compared with £582). Cost savings may also result from reduced hypnotic drug prescribing treatment. However, there is currently no published evidence to support these scenarios.

Sleepio is a digital technology and so no changes in NHS facilities or infrastructure should be needed.